JP7579589B2 - Ｒａｎタンパク質関連神経学的疾患を処置するための方法 - Google Patents

Ｒａｎタンパク質関連神経学的疾患を処置するための方法 Download PDF

Info

Publication number
JP7579589B2
JP7579589B2 JP2022500544A JP2022500544A JP7579589B2 JP 7579589 B2 JP7579589 B2 JP 7579589B2 JP 2022500544 A JP2022500544 A JP 2022500544A JP 2022500544 A JP2022500544 A JP 2022500544A JP 7579589 B2 JP7579589 B2 JP 7579589B2
Authority
JP
Japan
Prior art keywords
poly
seq
protein
ran
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538926A (ja
JPWO2021007110A5 (enExample
Inventor
ラヌム，ローラ
グェン，リーエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of JP2022538926A publication Critical patent/JP2022538926A/ja
Publication of JPWO2021007110A5 publication Critical patent/JPWO2021007110A5/ja
Priority to JP2024185014A priority Critical patent/JP2025026843A/ja
Application granted granted Critical
Publication of JP7579589B2 publication Critical patent/JP7579589B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
JP2022500544A 2019-07-05 2020-07-02 Ｒａｎタンパク質関連神経学的疾患を処置するための方法 Active JP7579589B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024185014A JP2025026843A (ja) 2019-07-05 2024-10-21 Ｒａｎタンパク質関連神経学的疾患を処置するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962871031P 2019-07-05 2019-07-05
US62/871,031 2019-07-05
US202063025096P 2020-05-14 2020-05-14
US63/025,096 2020-05-14
PCT/US2020/040725 WO2021007110A1 (en) 2019-07-05 2020-07-02 Methods for treating ran protein-associated neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024185014A Division JP2025026843A (ja) 2019-07-05 2024-10-21 Ｒａｎタンパク質関連神経学的疾患を処置するための方法

Publications (3)

Publication Number Publication Date
JP2022538926A JP2022538926A (ja) 2022-09-06
JPWO2021007110A5 JPWO2021007110A5 (enExample) 2023-07-10
JP7579589B2 true JP7579589B2 (ja) 2024-11-08

Family

ID=74114201

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022500544A Active JP7579589B2 (ja) 2019-07-05 2020-07-02 Ｒａｎタンパク質関連神経学的疾患を処置するための方法
JP2024185014A Pending JP2025026843A (ja) 2019-07-05 2024-10-21 Ｒａｎタンパク質関連神経学的疾患を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024185014A Pending JP2025026843A (ja) 2019-07-05 2024-10-21 Ｒａｎタンパク質関連神経学的疾患を処置するための方法

Country Status (6)

Country Link
US (1) US20220267776A1 (enExample)
EP (1) EP3994159A4 (enExample)
JP (2) JP7579589B2 (enExample)
AU (1) AU2020310843A1 (enExample)
CA (1) CA3145291A1 (enExample)
WO (1) WO2021007110A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10509045B2 (en) 2015-05-29 2019-12-17 University Of Florida Research Foundation, Incorporated Methods for diagnosing Huntington's disease
CA3019847A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
AU2018255293B2 (en) 2017-04-17 2024-03-07 University Of Florida Research Foundation, Incorporated Regulation of RAN translation by PKR and eIF2a-P pathways
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
AU2018338451A1 (en) 2017-09-25 2020-04-02 University Of Florida Research Foundation, Incorporated Immunoassays for detection of RAN proteins
JP7350337B2 (ja) 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
CA3154741A1 (en) 2019-09-20 2021-03-25 University Of Florida Research Foundation, Incorporated Detection of antibodies against ran proteins from serum and tissue lysates
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
EP4427049A4 (en) * 2021-11-01 2025-08-20 Univ Florida POLY-GA PROTEINS IN ALZHEIMER'S DISEASE
WO2023102111A1 (en) 2021-12-01 2023-06-08 University Of Florida Research Foundation, Incorporated Small molecule inhibitors of repeat associated non-aug (ran) translation and combination therapies
AU2023373378A1 (en) * 2022-11-01 2025-04-24 University Of Florida Research Foundation, Incorporated Interrupted ran proteins in disease
WO2024173816A1 (en) * 2023-02-17 2024-08-22 The University Of North Carolina At Chapel Hill Methods of detecting telomere-encoded dipeptide repeat proteins and therapeutic applications
CN116693621B (zh) * 2023-03-02 2023-11-14 东北农业大学 抑制革兰氏阴性菌的窄谱抗菌肽pc及其制备方法和应用
WO2025019730A1 (en) * 2023-07-20 2025-01-23 University Of Florida Research Foundation, Incorporated Engineered ga antibodies for therapy development
WO2025128551A1 (en) * 2023-12-11 2025-06-19 University Of Florida Research Foundation, Incorporated Aav-based anti-ga therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361166A1 (en) 2013-01-22 2015-12-17 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
JP2016515208A (ja) 2013-03-14 2016-05-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
JP2016108249A (ja) 2014-12-02 2016-06-20 国立大学法人 東京医科歯科大学 脊髄小脳失調症３１型（ｓｃａ３１）治療剤
WO2017176813A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
US20180292416A1 (en) 2015-05-29 2018-10-11 University Of Florida Research Foundation, Incorporated Methods for diagnosing huntington's disease
WO2019060918A1 (en) 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955086A1 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
JP2020534253A (ja) * 2017-08-08 2020-11-26 ウェーブ ライフ サイエンシーズ リミテッド オリゴヌクレオチド組成物及びその方法
JP7350337B2 (ja) * 2017-09-26 2023-09-26 ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． 神経障害の処置においてｒａｎタンパク質レベルを低下させるためのメトホルミンおよびそのアナログの使用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150361166A1 (en) 2013-01-22 2015-12-17 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
JP2016515208A (ja) 2013-03-14 2016-05-26 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ａｌｓ関連ジアミノ酸リピート含有タンパク質
JP2016108249A (ja) 2014-12-02 2016-06-20 国立大学法人 東京医科歯科大学 脊髄小脳失調症３１型（ｓｃａ３１）治療剤
US20180292416A1 (en) 2015-05-29 2018-10-11 University Of Florida Research Foundation, Incorporated Methods for diagnosing huntington's disease
WO2017176813A1 (en) 2016-04-04 2017-10-12 University Of Florida Research Foundation, Incorporated Manipulation of eif3 to modulate repeat associated non-atg (ran) translation
WO2019060918A1 (en) 2017-09-25 2019-03-28 University Of Florida Research Foundation, Incorporated IMMUNOLOGICAL ASSAYS FOR DETECTION OF RAN PROTEINS

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
Melinda L Moseley，Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8，NATURE GENETICS，2006年06月25日，Vol.38 No.7，Page.758-769
Tao Zu，RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2，Neuron，2017年09月13日，Vol.95，Page.1292-1305
Xin Liu，In Situ Capture of Chromatin Interactions by Biotinylated dCas9，Cell，2017年08月24日，Vol.170，Page.1028-1043
Yuanjing Liu，C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD，Neuron，2016年05月04日，Vol.90，Page.521-534
佐々木 秀直，4．脊髄小脳変性症 最近の進歩，日本内科学会雑誌，2013年09月10日，102巻 9号，Page.2375-2381
佐々木秀直，SCA14における起因遺伝子の検索 (厚生労働省S)，運動失調に関する調査及び病態機序に関する研究班 平成13年度研究報告書，2002年，Page.67-68
名宮井尊史，リピート病の病態機構UPDATE―RNA毒性とRAN翻訳 Fuchs角膜内皮変性症におけるリピート病態，医学のあゆみ，2018年12月22日，Vol.267 No.11/12，Page.814-816
塩田 倫史，リピート病におけるRNA毒性仮説とRAN翻訳仮説，日本薬理学雑誌，2017年，150巻 3号，Pgae.165
塩田倫史，脆弱X関連振戦/失調症候群(FXTAS)におけるRANタンパク質FMRpolyGの産生と病態との関与，日本生化学会大会，2017年，Vol.90th，Page.ROMBUNNO.3PW23-5
宮崎雄，リピート病の病態機構UPDATE―RNA毒性とRAN翻訳 トリプレットリピート病におけるRAN翻訳の関与，医学のあゆみ，2018年12月22日，Vol.267 No.11/12，Page.823-829
後藤順，トリプレットリピート病UPDATE トリプレットリピート病とは，医学のあゆみ，2006年10月28日，Vol.219 No.4，Page.241-244
永井義隆，コンフォメーション病としての神経変性疾患，ファルマシア，2013年09月01日，Vol.49 No.9，Page.849-853
永井義隆，特集 神経細胞変性のメカニズム ポリグルタミン病における神経変性，BRAIN MEDICAL，2014年10月，Vol.26 No.3，Page.225-229
石川欽也，＜シンポジウム 29―2＞脊髄小脳変性症 update 脊髄小脳失調症（SCA31）の分子病態解明，臨床神経，2011年，Vol.51，Paeg.1122-1124

Also Published As

Publication number Publication date
AU2020310843A1 (en) 2022-01-20
CA3145291A1 (en) 2021-01-14
EP3994159A4 (en) 2023-08-09
JP2022538926A (ja) 2022-09-06
JP2025026843A (ja) 2025-02-26
WO2021007110A1 (en) 2021-01-14
EP3994159A1 (en) 2022-05-11
US20220267776A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
JP7579589B2 (ja) Ｒａｎタンパク質関連神経学的疾患を処置するための方法
US20230381308A1 (en) Neutralizing anti-tl1a monoclonal antibodies
TWI730963B (zh) 抗-ｔａｕ抗體及使用方法
CN110172098B (zh) 抗α-突触核蛋白的单克隆抗体及其应用
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
JP2022058369A (ja) アルツハイマー病治療方法
US20250243263A1 (en) Tau binding compounds
JP2025528797A (ja) トランスフェリン受容体結合タンパク質及びコンジュゲート
JP2024026683A (ja) 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法
JP2020506221A (ja) バイオフィルム関連障害の処置のための抗体断片
US20250164489A1 (en) Ran proteins in sporadic amyotrophic lateral sclerosis
US20240426844A1 (en) Poly-ga proteins in alzheimer’s disease
WO2021012082A1 (zh) β—淀粉样蛋白环状核糖核酸、多肽及其应用
EP4427049A1 (en) Poly-ga proteins in alzheimer's disease
WO2016049662A1 (en) Methods and compositions for treating age-related disorders
CN110317814A (zh) β-淀粉样蛋白环状核糖核酸、多肽及其应用
EP4612175A1 (en) Interrupted ran proteins in disease
WO2025019730A1 (en) Engineered ga antibodies for therapy development
CN119730880A (zh) 肌萎缩侧索硬化症、帕金森病、亨廷顿病、脊髓小脑性共济失调、与老化有关的变性疾病或神经疾病、脑老化、或者伴有脑老化的疾病的预防剂或治疗剂
HK40022840B (zh) 抗α-突触核蛋白抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230630

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240723

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240919

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241021

R150 Certificate of patent or registration of utility model

Ref document number: 7579589

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150